An update on the use of ambrisentan in pulmonary arterial hypertension
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An update on the use of ambrisentan in pulmonary arterial hypertension
Authors
Keywords
-
Journal
Therapeutic Advances in Respiratory Disease
Volume 6, Issue 6, Pages 331-343
Publisher
SAGE Publications
Online
2012-08-30
DOI
10.1177/1753465812458014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ambrisentan for pulmonary arterial hypertension: Long term effects on clinical status, exercise capacity and haemodynamics
- (2012) Michele D'Alto et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Combination Therapy Improves Exercise Capacity and Reduces Risk of Clinical Worsening in Patients With Pulmonary Arterial Hypertension
- (2012) Bing Zhu et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- 57 ATHENA-1: Long Term Clinical Improvements Following the Addition of Ambrisentan to Background PDE5i Therapy in Patients with Pulmonary Arterial Hypertension
- (2012) S. Shapiro et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension
- (2012) Ori Ben-Yehuda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension
- (2011) James R. Klinger et al. AMERICAN JOURNAL OF CARDIOLOGY
- Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease
- (2011) Warren A. Zuckerman et al. AMERICAN JOURNAL OF CARDIOLOGY
- Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis
- (2011) Yuanyuan Bai et al. CARDIOLOGY
- ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension
- (2011) David B. Badesch et al. Cardiovascular Therapeutics
- ATHENA-1: Hemodynamic Improvements Following the Addition of Ambrisentan to Background PDE5i Therapy in Patients With Pulmonary Arterial Hypertension
- (2011) Ronald Oudiz et al. CHEST
- Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension: 3-Year Outcome
- (2011) Ronald Oudiz et al. CHEST
- Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension
- (2011) Shunji Yoshida et al. CURRENT MEDICAL RESEARCH AND OPINION
- Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension
- (2011) W.-T. N. Lee et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmacokinetic evaluation of ambrisentan
- (2011) Mitchell S Buckley et al. Expert Opinion on Drug Metabolism & Toxicology
- Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.
- (2010) J. Craig Hartman et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension
- (2010) Rodrigo Cartin-Ceba et al. CHEST
- Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine
- (2010) R Spence et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers
- (2009) Gennyne Walker et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
- (2009) et al. EUROPEAN HEART JOURNAL
- Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy
- (2009) M. M. Hoeper et al. EUROPEAN RESPIRATORY JOURNAL
- Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
- (2009) A. Lavelle et al. EUROPEAN RESPIRATORY JOURNAL
- Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
- (2009) M. M. Hoeper EUROPEAN RESPIRATORY JOURNAL
- Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension
- (2009) Shannon E. Blalock et al. JOURNAL OF CARDIAC FAILURE
- Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
- (2009) Ronald J. Oudiz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
- (2009) Paul M. Hassoun et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
- (2008) Michael D. McGoon et al. CHEST
- Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
- (2008) Nazzareno Galiè et al. CIRCULATION
- Pathogenic mechanisms of pulmonary arterial hypertension
- (2007) Stephen Y. Chan et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started